Paid Clinical Trials for Merkel Cell Carcinoma

Showing all 7 results

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

by CTG

in Merkel Cell Carcinoma, Skin Cancer

Other

Florida

Deadline:

09/01/2026

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

by CTG

in Urothelial Carcinoma, Small Cell Lung Cancer, Merkel Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer

Other

Alaska

Deadline:

12/31/2030

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

by CTG

in Merkel Cell Carcinoma

Other

New Jersey

Deadline:

03/01/2026

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

by CTG

in Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma

Other

Florida

Deadline:

03/01/2028

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

by CTG

in Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma

Other

Florida

Deadline:

12/01/2026

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

by CTG

in Merkel Cell Carcinoma

Other

Iowa

Deadline:

09/01/2026

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

by CTG

in Merkel Cell Carcinoma

Other

Texas

Deadline:

09/01/2028

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Merkel Cell Carcinoma

Filter Results:

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps